• Profile
Close

Erythropoietin in traumatic brain injury associated acute kidney injury: A randomized controlled trial

Acta Anaesthesiologica Scandinavica Aug 25, 2018

Skrifvars MB, et al. - Researchers focused on acute kidney injury (AKI) as well as its prevention using erythropoietin (EPO) in this pre-planned analysis of patients with traumatic brain injury (TBI) who were randomized to weekly EPO (40 000 units) or placebo (0.9% sodium chloride) subcutaneously up to three doses or until intensive care unit (ICU) discharge in the EPO-TBI trial. Using the Kidney Disease Improving Global Outcome (KDIGO) classification, categorization of creatinine levels and urinary output (up to 7 days) was done. A more common development of AKI was observed in male patients and those with severe vs moderate TBI. AKI appeared to be related to worse outcome. Predictors of time to AKI were male gender and severity of TBI. Time to mortality was predicted by KDIGO stage 1, KDIGO stage 2 and KDIGO stage 3. EPO did not prevent AKI after TBI.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay